Shanghai Henlius Biotech, Inc. Class H (2696) Stock Forecast & Price Target

Compare

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2696 Analyst Ratings

Moderate Buy

1 Buy

0 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Shanghai

Henlius Biotech, Inc. Class H

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2696 Stock 12 Month Forecast

Average Price Target

HK$100.70

▲(66.31% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Shanghai Henlius Biotech, Inc. Class H in the last 3 months. The average price target is HK$100.70 with a high forecast of HK$100.70 and a low forecast of HK$100.70. The average price target represents a 66.31% change from the last price of HK$60.55.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"HK$21","41":"HK$41","61":"HK$61","81":"HK$81","101":"HK$101"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$100.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$100.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$100.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,41,61,81,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"May<br/>2024","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.85,72.22307692307692,74.59615384615384,76.96923076923076,79.34230769230768,81.71538461538461,84.08846153846153,86.46153846153845,88.83461538461538,91.2076923076923,93.58076923076922,95.95384615384616,98.32692307692308,{"y":100.7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.85,72.22307692307692,74.59615384615384,76.96923076923076,79.34230769230768,81.71538461538461,84.08846153846153,86.46153846153845,88.83461538461538,91.2076923076923,93.58076923076922,95.95384615384616,98.32692307692308,{"y":100.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.85,72.22307692307692,74.59615384615384,76.96923076923076,79.34230769230768,81.71538461538461,84.08846153846153,86.46153846153845,88.83461538461538,91.2076923076923,93.58076923076922,95.95384615384616,98.32692307692308,{"y":100.7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.9,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.9,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.9,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.9,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.9,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.9,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.9,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.3,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$100.70

Average Price TargetHK$100.70

Lowest Price TargetHK$100.70

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ziyi Chen

Goldman Sachs

HK$100.7

Buy

66.31%

Upside

Initiated

10/30/25

Next-gen IO-ADC to lead pipeline globalization; initiate at 2025 | 9:53PM HKT | Research | Equity We initiate coverage on Buy rating and a risk-adjusted DCF-based 12-month TP of HK$100.70. Henlius Biotech is strategically evolving from an early mover in biosimilar to a global innovative biopharma. The transition is well supported by 1) an expanding pipeline led by key assets HLX43, which emerges as a potential best-in-class pan-tumor PD-L1 ADC poised for global pivotal studies; 2) a global biosimilar franchise to provide meaningful cash flow to drive R&D; and 3) early- proven global capabilities in clinical operations, regulatory affairs and biomanufacturing.

Unknown Analyst

TFI Asset Management

Not Ranked

TFI Asset Management

HK$120.87

Buy

99.62%

Upside

Reiterated

09/16/25

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$130

Buy

114.70%

Upside

Reiterated

08/28/25

Jill Wu

CMB International Securities

HK$61.98→HK$97.75

Buy

61.44%

Upside

Reiterated

08/27/25

Shanghai Henlius Biotech: Strong Financial Performance and Promising Product Pipeline Drive Buy Rating

Unknown Analyst

CICC

Not Ranked

CICC

HK$102.91

Buy

69.96%

Upside

Reiterated

08/26/25

Unknown Analyst

Citi

Not Ranked

Citi

HK$95

Buy

56.90%

Upside

Reiterated

08/13/25

Unknown Analyst

TFI Asset Management

Not Ranked

TFI Asset Management

HK$78.01

Buy

28.84%

Upside

Reiterated

06/29/25

Unknown Analyst

SWS Res

Not Ranked

SWS Res

HK$71

Buy

17.26%

Upside

Reiterated

06/27/25

Unknown Analyst

TFI Asset Management

Not Ranked

TFI Asset Management

HK$61.59

Buy

1.72%

Upside

Reiterated

04/27/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ziyi Chen

Goldman Sachs

HK$100.7

Buy

66.31%

Upside

Initiated

10/30/25

Unknown Analyst

TFI Asset Management

Not Ranked

TFI Asset Management

HK$120.87

Buy

99.62%

Upside

Reiterated

09/16/25

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$130

Buy

114.70%

Upside

Reiterated

08/28/25

Jill Wu

CMB International Securities

HK$61.98→HK$97.75

Buy

61.44%

Upside

Reiterated

08/27/25

Shanghai Henlius Biotech: Strong Financial Performance and Promising Product Pipeline Drive Buy Rating

Unknown Analyst

CICC

Not Ranked

CICC

HK$102.91

Buy

69.96%

Upside

Reiterated

08/26/25

Unknown Analyst

Citi

Not Ranked

Citi

HK$95

Buy

56.90%

Upside

Reiterated

08/13/25

Unknown Analyst

TFI Asset Management

Not Ranked

TFI Asset Management

HK$78.01

Buy

28.84%

Upside

Reiterated

06/29/25

Unknown Analyst

SWS Res

Not Ranked

SWS Res

HK$71

Buy

17.26%

Upside

Reiterated

06/27/25

Unknown Analyst

TFI Asset Management

Not Ranked

TFI Asset Management

HK$61.59

Buy

1.72%

Upside

Reiterated

04/27/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Shanghai Henlius Biotech, Inc. Class H

1 Month

xxx

Success Rate

3/6 ratings generated profit

Average Return

+5.98%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +5.98% per trade.

3 Months

xxx

Success Rate

5/6 ratings generated profit

Average Return

+27.37%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +27.37% per trade.

1 Year

Jill WuCMB International Securities

Success Rate

5/6 ratings generated profit

Average Return

+62.78%

reiterated a buy rating 4 months ago

Copying Jill Wu's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +62.78% per trade.

2 Years

xxx

Success Rate

5/6 ratings generated profit

Average Return

+250.68%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +250.68% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2696 Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2696 has received 2 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 2696 average Analyst price target in the past 3 months is 100.70.

Each month's total comprises the sum of three months' worth of ratings.

2696 Financial Forecast

2696 Earnings Forecast

The previous quarter’s earnings for 2696 were HK$0.87.

2696 Sales Forecast

The previous quarter’s earnings for 2696 were HK$3.23B.

2696 Stock Forecast FAQ

What is HK:2696’s average 12-month price target, according to analysts?

Based on analyst ratings, Shanghai Henlius Biotech, Inc. Class H’s 12-month average price target is 100.70.

What is HK:2696’s upside potential, based on the analysts’ average price target?

Shanghai Henlius Biotech, Inc. Class H has 66.31% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Shanghai Henlius Biotech, Inc. Class H a Buy, Sell or Hold?

Shanghai Henlius Biotech, Inc. Class H has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is Shanghai Henlius Biotech, Inc. Class H’s share price target?

The average share price target for Shanghai Henlius Biotech, Inc. Class H is 100.70. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$100.70 ,and the lowest forecast is HK$100.70. The average share price target represents 66.31% Increase from the current price of HK$60.55.

What do analysts say about Shanghai Henlius Biotech, Inc. Class H?

Shanghai Henlius Biotech, Inc. Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Shanghai Henlius Biotech, Inc. Class H?

To buy shares of HK:2696, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Shanghai Henlius Biotech, Inc. Class H (2696) Stock Forecast & Price Target

2696 Analyst Ratings

2696 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Shanghai Henlius Biotech, Inc. Class H

2696 Analyst Recommendation Trends

2696 Financial Forecast

2696 Earnings Forecast

2696 Sales Forecast

2696 Stock Forecast FAQ

Detailed List of Analyst Forecasts